Global Cell and Gene Therapy CDMO Market Insights, Size, and Forecast By Application Indication (Oncology, Immunology, Neurology, Cardiovascular, Other Diseases), By Product (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global Cell and Gene Therapy CDMO Market is projected to grow from USD 19.8 Billion in 2025 to USD 74.8 Billion by 2035, reflecting a compound annual growth rate of 18.7% from 2026 through 2035.
Global Cell and Gene Therapy CDMO Market Market Value (USD Billion) Analysis, 2025-2035
The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) market encompasses the specialized services offered by third-party organizations for the development, manufacturing, and commercialization of cell and gene therapy products. This market is characterized by a surge in research and development activities, driven by the increasing prevalence of chronic and rare diseases, alongside significant technological advancements in genetic engineering and cell culturing techniques. Key market drivers include the growing number of cell and gene therapy products in clinical trials, the complex and capital-intensive nature of manufacturing these advanced therapies, and the necessity for specialized expertise and infrastructure that many biopharmaceutical companies lack internally. Furthermore, the rising investment from venture capitalists and pharmaceutical companies into cell and gene therapy startups is fueling demand for CDMO services. However, market growth is tempered by stringent regulatory requirements, the high cost of therapy development and manufacturing, and challenges related to scalability and quality control. Opportunities abound in the development of innovative manufacturing platforms, expansion into emerging therapeutic areas beyond oncology, and strategic partnerships between CDMOs and therapy developers to streamline production processes and accelerate market access.
A prominent trend shaping the market is the increasing adoption of advanced manufacturing technologies, such as automation, digitalization, and continuous manufacturing processes, aimed at improving efficiency, reducing costs, and enhancing product quality. There is also a notable shift towards integrated service offerings, where CDMOs provide end-to-end solutions from process development to commercial manufacturing, thereby simplifying the supply chain for their clients. North America currently dominates the market, primarily due to the presence of a robust biopharmaceutical industry, significant R&D investments, advanced healthcare infrastructure, and a supportive regulatory environment that fosters innovation. The Asia Pacific region is emerging as the fastest-growing market, driven by increasing healthcare expenditure, a large patient pool, growing government support for biotechnology, and the establishment of new manufacturing facilities by both local and international players seeking cost-effective production options and market expansion. The oncology segment, encompassing therapies for various cancers, remains the leading application indication, propelled by the high unmet medical need and the breakthrough potential of cell and gene therapies in this area. Key players such as Genscript, Syngene, Thermo Fisher Scientific, Eurofins, Wacker, Curia, Pfizer CentreOne, Charles River Laboratories, Recipharm, and Lonza are actively pursuing strategies like capacity expansion, technological innovation, strategic acquisitions, and collaborative partnerships to strengthen their market position and capitalize on the burgeoning demand for specialized CDMO services. These strategies are critical for navigating the complexities of this rapidly evolving and highly specialized market.
Quick Stats
Market Size (2025):
USD 19.8 BillionProjected Market Size (2035):
USD 74.8 BillionLeading Segment:
Oncology (62.4% Share)Dominant Region (2025):
North America (48.5% Share)CAGR (2026-2035):
18.7%
Global Cell and Gene Therapy CDMO Market Emerging Trends and Insights
AI-Powered Process Optimization: Revolutionizing CGT Manufacturing Efficiency
AI-powered process optimization is transforming Cell and Gene Therapy (CGT) manufacturing. This trend leverages Artificial Intelligence to analyze vast datasets from bioreactors, purification, and fill/finish operations. By identifying bottlenecks, predicting equipment failures, and optimizing resource allocation in real-time, AI enhances production yields and reduces batch failures. It automates complex decision-making, streamlines workflows, and ensures consistent product quality, moving CGT CDMOs towards a more agile, cost-effective, and scalable manufacturing paradigm. This revolution minimizes human error, accelerates time-to-market for vital therapies, and ultimately increases accessibility to life-changing treatments by boosting overall efficiency and reliability across the entire manufacturing lifecycle.
Decentralized Biomanufacturing: Scaling Localized CGT Production Networks
Decentralized biomanufacturing in CGT signifies a shift from large, central facilities to smaller, regionally distributed production sites. This trend aims to overcome current manufacturing bottlenecks by localizing production closer to clinical trial sites and patient populations. Instead of a few major hubs, we see the emergence of a network of agile, adaptable facilities.
This model allows for faster development-to-market timelines for new therapies, reduces logistical complexities inherent in transporting live cell products, and enhances supply chain resilience. It supports tailored, patient-specific therapies by facilitating closer collaboration between researchers, clinicians, and manufacturers at a local level. The focus is on scalable, modular production units that can be deployed globally, creating a more responsive and efficient ecosystem for CGT delivery.
Next-Gen Analytics & Real-Time Monitoring: Enhancing CGT Quality and Compliance
Next-Gen Analytics & Real-Time Monitoring is revolutionizing CGT manufacturing by providing unprecedented insight into critical processes. This trend involves implementing advanced sensor technologies and sophisticated data analytics platforms across the CDMO value chain. By capturing and analyzing data from raw material inspection through final product release, facilities can proactively identify and address potential quality deviations. Real-time monitoring allows for immediate intervention, reducing batch failures and ensuring product consistency. This data-driven approach enhances compliance with stringent regulatory requirements by providing robust documentation and traceability. Ultimately, it optimizes process efficiency, strengthens quality control, and builds greater confidence in the safety and efficacy of CGTs manufactured by CDMOs.
What are the Key Drivers Shaping the Global Cell and Gene Therapy CDMO Market
Surging Biopharmaceutical R&D and Clinical Pipeline Expansion
The rapidly expanding landscape of cell and gene therapies is a primary driver for the CDMO market. Breakthroughs in gene editing, cell reprogramming, and vector design are leading to a proliferation of novel drug candidates. This translates into a substantial increase in pre-clinical and clinical trials, as biopharmaceutical companies aggressively pursue new treatments for a range of diseases, from rare genetic disorders to common cancers. The complexity and specialized manufacturing requirements of these advanced therapies necessitate outsourcing to experienced CDMOs. As more therapies move through development stages towards commercialization, the demand for specialized expertise, infrastructure, and regulatory compliance provided by CDMOs intensifies, directly fueling market growth.
Escalating Demand for Advanced CGT Manufacturing Capabilities
The global cell and gene therapy (CGT) market is experiencing a significant surge in demand for sophisticated manufacturing capabilities. As more CGT candidates progress through clinical trials and receive regulatory approval, there's a critical need for specialized Contract Development and Manufacturing Organizations (CDMOs). These therapies, often complex and individualized, require highly specialized processes for cell expansion, viral vector production, gene editing, and aseptic fill-finish. The increasing volume and diversity of CGT products entering the pipeline necessitates advanced infrastructure, skilled personnel, and robust quality control systems that many pharmaceutical companies lack internally. This unmet manufacturing capacity, coupled with the intricate nature of CGT production, fuels the demand for expert CDMO partners capable of scaling up production while ensuring product quality and regulatory compliance.
Strategic Partnerships and Consolidations Enhancing Service Offerings
Strategic partnerships and consolidations are a significant driver in the Global Cell and Gene Therapy CDMO market, propelling growth by expanding the service portfolios and capabilities of Contract Development and Manufacturing Organizations. As the complexity of cell and gene therapies increases, CDMOs are forming alliances or acquiring specialized entities to offer comprehensive end-to-end solutions, from process development and analytical testing to clinical manufacturing and commercial supply. These collaborations enable CDMOs to access novel technologies, specialized expertise, and additional capacity, addressing critical bottlenecks in the manufacturing pipeline. By integrating diverse offerings, CDMOs can provide more robust, integrated, and efficient services to their biopharmaceutical clients, accelerating the development and commercialization of these innovative therapies and ultimately meeting the escalating demand within the market.
Global Cell and Gene Therapy CDMO Market Restraints
Stringent Regulatory Landscape and Approval Delays
The stringent regulatory landscape presents a significant hurdle for the global cell and gene therapy CDMO market. These therapies, often novel and complex, face rigorous scrutiny from health authorities worldwide, including the FDA, EMA, and PMDA. The extensive pre-clinical and clinical trial requirements, coupled with evolving Good Manufacturing Practice (GMP) standards, necessitate substantial investments in time and resources.
Approval delays are a direct consequence, as each stage, from Investigational New Drug (IND) applications to Biologics License Applications (BLA), involves comprehensive data submission and review processes. Manufacturing facility certifications and process validation add further layers of complexity and extend timelines. This regulatory burden escalates development costs and prolongs time-to-market, impacting client profitability and CDMO capacity utilization. The dynamic nature of regulations also demands continuous adaptation, posing ongoing operational challenges.
High Capital Investment and Specialized Infrastructure Requirements
The Global Cell and Gene Therapy CDMO market is significantly restrained by the need for high capital investment and specialized infrastructure. Developing and manufacturing these advanced therapies necessitates state-of-the-art facilities equipped with specialized cleanrooms, sophisticated bioreactors, and advanced analytical instruments. These facilities must adhere to stringent regulatory standards like cGMP, requiring extensive investment in design, construction, and validation.
Furthermore, the unique biological nature of cell and gene therapies demands specialized capabilities for handling live cells, viral vectors, and sensitive biomolecules. This includes controlled temperature storage, aseptic processing environments, and highly trained personnel. Established CDMOs or new entrants face substantial upfront costs to build or adapt infrastructure to meet these exacting requirements, creating a high barrier to entry and limiting the agility and expansion capabilities within the market. This financial burden often translates into higher service costs, impacting therapy developers.
Global Cell and Gene Therapy CDMO Market Opportunities
Capitalizing on the Manufacturing Capacity Crunch for Viral Vectors and Plasmid DNA
The booming cell and gene therapy pipeline has created a critical manufacturing bottleneck. Demand for essential raw materials, specifically viral vectors and plasmid DNA, far outstrips supply due to their complex production requirements. This capacity crunch presents a prime opportunity for CDMOs. Many therapy developers lack the specialized in-house facilities and expertise for large-scale production, leading to long wait times and supply chain risks. CDMOs that proactively invest in expanding their dedicated viral vector and plasmid DNA manufacturing capabilities can become indispensable partners. By offering reliable, scalable, and GMP-grade production, they solve this crucial industry-wide problem. This strategic positioning enables them to command premium pricing, secure long-term contracts, and attract a broad client base seeking to accelerate their therapies from clinical development to commercialization, ensuring a vital role in the ecosystem's overall growth.
Emergence of End-to-End Service Platforms for Seamless Clinical-to-Commercial Transition
The complex journey from clinical trials to commercial-scale manufacturing is a primary bottleneck for cell and gene therapy developers. This creates a pivotal opportunity for CDMOs offering end-to-end service platforms. These integrated solutions provide a single-partner framework, managing the entire lifecycle from early process development, viral vector production, and analytical testing through to commercial GMP manufacturing and logistics.
For therapy innovators, particularly smaller biotechs, this model de-risks development by eliminating the need for complex, costly, and time-consuming technology transfers between multiple vendors. It provides a seamless, scalable pathway to market. For CDMOs, this strategy fosters deep, long-term partnerships, transforming them from transactional service providers into indispensable strategic partners. It secures high-value, long-term revenue streams and creates a powerful competitive advantage by capturing a product’s entire manufacturing journey, from concept to commercial reality.
Global Cell and Gene Therapy CDMO Market Segmentation Analysis
Key Market Segments
By Product
- •Cell Therapy
- •Gene Therapy
- •Gene-Modified Cell Therapy
By Application Indication
- •Oncology
- •Immunology
- •Neurology
- •Cardiovascular
- •Other Diseases
Why does the oncology segment overwhelmingly dominate the Global Cell and Gene Therapy CDMO market?
The segment's leadership stems from the massive pipeline of cancer-related treatments, especially CAR-T therapies. High cancer prevalence fuels intense investment, creating sustained demand for specialized CDMOs. These partners are crucial for navigating complex manufacturing, scaling production, and managing the intricate supply chains required for these oncological treatments, which constitute a significant majority of the market.
How do the different product segments influence CDMO service requirements?
Each product presents unique manufacturing challenges. Cell therapy services cater to both patient-specific (autologous) and off-the-shelf (allogeneic) models. Gene therapy requires deep expertise in viral vector production. Gene-modified cell therapies are the most complex, demanding integrated capabilities that combine advanced gene editing with sophisticated cell processing, pushing CDMOs to offer comprehensive end-to-end solutions.
Which application areas beyond oncology are creating new growth opportunities for CDMOs?
While oncology leads, indications like immunology and neurology are key growth drivers. There is rising demand for CDMOs to support therapies for autoimmune disorders, neurodegenerative conditions, and various rare genetic diseases. This diversification compels CDMOs to broaden their expertise and platform technologies to address the specific manufacturing needs of these emerging therapeutic fields, including cardiovascular applications.
Global Cell and Gene Therapy CDMO Market Regulatory and Policy Environment Analysis
The global cell and gene therapy CDMO market operates within a complex and dynamically evolving regulatory framework. Key agencies like the U.S. FDA, EMA, and Japan's PMDA are continuously refining guidelines for product development, manufacturing, and quality control. While efforts towards international harmonization via bodies like the ICH aim to streamline global processes, CDMOs still face significant challenges in navigating disparate regional requirements for GMP, raw material sourcing, and analytical comparability.
Expedited approval pathways, such as the FDA's RMAT and EMA's PRIME schemes, accelerate development timelines but intensify pressure on CDMOs to uphold stringent quality and compliance standards. Supportive government policies and funding initiatives foster growth, yet they also heighten scrutiny. Success for CDMOs fundamentally hinges on their ability to demonstrate regulatory agility, invest in robust quality management systems, and provide strategic guidance to clients navigating this intricate and high-stakes environment.
Which Emerging Technologies Are Driving New Trends in the Market?
The cell and gene therapy CDMO market is rapidly evolving through technological integration aimed at enhancing scalability and reducing costs. Automation and robotics are becoming standard in manufacturing workflows, minimizing manual errors and ensuring process consistency for both autologous and allogeneic therapies. Artificial intelligence and machine learning are being leveraged for predictive analytics in process development and supply chain optimization, improving manufacturing success rates.
Innovations in vector production, including advanced producer cell lines for AAV and novel non-viral delivery systems, are expanding therapeutic possibilities. Furthermore, CDMOs are incorporating next-generation gene editing tools and implementing Process Analytical Technology (PAT) for real-time quality control. Digital platforms providing end-to-end "vein-to-vein" tracking are also critical, ensuring robust chain of custody for these personalized medicines. These advancements are pivotal for industrializing complex therapies and broadening patient access, defining the competitive landscape for contract manufacturing partners.
Global Cell and Gene Therapy CDMO Market Regional Analysis
Global Cell and Gene Therapy CDMO Market Regional Analysis in 2025
North America is Expected to Hold the Largest Global Cell and Gene Therapy CDMO Market Market Share
Dominant Region
North America · 48.5% share
North America dominates the global Cell and Gene Therapy CDMO market, commanding a substantial 48.5% market share. This robust performance is underpinned by a confluence of factors, including a highly developed biopharmaceutical industry, a strong research and development ecosystem, and significant investment in advanced therapies. The presence of numerous leading pharmaceutical and biotechnology companies, coupled with well-established regulatory frameworks, fosters a conducive environment for CDMO growth. Furthermore, a high concentration of academic institutions and research centers, actively engaged in cutting-edge cell and gene therapy research, drives demand for specialized manufacturing and development services. The region's market size of USD 19.8 billion reflects this strong leadership.
Fastest Growing Region
Asia Pacific · 29.2% CAGR
The Asia Pacific region is poised for remarkable expansion within the global Cell and Gene Therapy CDMO market, projected to be the fastest-growing region with a robust CAGR of 29.2% from 2026 to 2035. This surge is primarily fueled by increasing government support for biotechnology and pharmaceutical R&D, particularly in countries like China, Japan, and South Korea. Furthermore, a rising prevalence of chronic and genetic diseases, coupled with growing awareness and adoption of advanced therapies, is creating a significant demand for specialized manufacturing services. The presence of a large patient pool, evolving regulatory frameworks, and competitive manufacturing costs are also attracting global CDMOs and fostering local industry growth across the Asia Pacific landscape.
Impact of Geopolitical and Macroeconomic Factors
Geopolitically, the cell and gene therapy (CGT) CDMO market is characterized by a concentrated innovation ecosystem, primarily in North America, driving significant R&D and manufacturing investment. This regional dominance creates a competitive landscape for attracting skilled labor and advanced manufacturing capabilities. Geopolitical tensions, particularly regarding intellectual property rights and trade policies, could disrupt global supply chains for critical raw materials and specialized equipment, impacting the ability of CDMOs to meet growing demand. Furthermore, varying regulatory frameworks across regions pose a challenge for global market penetration and harmonization of manufacturing standards.
From a macroeconomic perspective, sustained venture capital and private equity funding in the biotech sector continues to fuel the expansion of CGT companies, directly increasing demand for CDMO services. However, rising interest rates and inflationary pressures could potentially cool investment, impacting the long-term growth trajectory. Healthcare spending trends, driven by an aging global population and increasing prevalence of chronic diseases, provide a fundamental tailwind for CGT therapies, ensuring a steady client base for CDMOs. Economic stability in key markets, especially North America, directly influences healthcare budgets and access to innovative treatments.
Recent Developments
- March 2025
Thermo Fisher Scientific announced a strategic initiative to expand its viral vector manufacturing capacity in Europe. This expansion aims to meet the surging demand for gene therapy vectors and reduce lead times for its clients.
- January 2025
Lonza entered into a long-term partnership with a prominent biotech company for the commercial manufacturing of an investigational allogeneic cell therapy. This collaboration solidifies Lonza's position as a key CDMO in the advanced cell therapy space.
- November 2024
Charles River Laboratories acquired a specialized analytical testing company focused on advanced therapy medicinal products (ATMPs). This acquisition enhances Charles River's comprehensive service offering for cell and gene therapy developers, particularly in critical quality control and safety testing.
- September 2024
Genscript launched a new high-throughput plasmid DNA manufacturing service specifically tailored for gene therapy applications. This service aims to provide faster turnaround times and increased scalability for early-stage development and clinical trial material production.
Key Players Analysis
The global Cell and Gene Therapy (CGT) CDMO market is characterized by a mix of established life science giants and specialized pure-play CDMOs, each leveraging distinct strengths. Lonza stands out as a leading pure-play CDMO, renowned for its extensive expertise across the CGT value chain, from process development to large-scale commercial manufacturing. Their advanced bioprocessing technologies, including viral vector production and cell manufacturing platforms, coupled with a robust regulatory track record, enable them to secure high-value partnerships. Similarly, Charles River Laboratories, though broader in its offerings, has significantly expanded its CGT CDMO capabilities, particularly in analytical testing and early-stage development, making them a critical partner for emerging biotechs. Thermo Fisher Scientific, a life science behemoth, offers comprehensive solutions spanning research tools, raw materials, and CDMO services, leveraging its vast infrastructure and technological prowess to capture a significant market share.
Strategic initiatives among these key players revolve around capacity expansion, technological innovation, and vertical integration to meet the surging demand for CGT manufacturing. Genscript and Syngene, while perhaps having a broader portfolio beyond just CGT CDMO, are increasing their focus and investment in this specialized area, offering cost-effective and scalable solutions, particularly for Asian markets. Pfizer CentreOne, a captive CDMO arm of Pfizer, offers a unique value proposition, leveraging Pfizer's global manufacturing footprint and regulatory experience, often serving as a trusted partner for complex projects. Wacker and Eurofins bring specialized capabilities, with Wacker focusing on biologics and viral vector manufacturing, and Eurofins on critical analytical testing services. Curia and Recipharm are also actively expanding their CGT capabilities through strategic acquisitions and investments in new facilities, all driven by the burgeoning pipeline of CGT therapies, the need for specialized manufacturing expertise, and the increasing outsourcing trend in the biopharmaceutical industry.
List of Key Companies:
- Genscript
- Syngene
- Thermo Fisher Scientific
- Eurofins
- Wacker
- Curia
- Pfizer CentreOne
- Charles River Lobaoraties
- Recipharm
- Lonza
- FUJIFILM Diosynth Biotechnologies
- Emergent BioSolutions
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 19.8 Billion |
| Forecast Value (2035) | USD 74.8 Billion |
| CAGR (2026-2035) | 18.7% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
Figure 1: Global Cell and Gene Therapy CDMO Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2035
Figure 2: Global Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025 & 2035
Figure 3: Global Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025 & 2035
Figure 4: Global Cell and Gene Therapy CDMO Market Value Share (%), by Region, 2025 & 2035
Figure 5: North America Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 6: North America Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 7: North America Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 8: North America Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 9: North America Cell and Gene Therapy CDMO Market Value (USD billion), by Country, 2025 & 2035
Figure 10: North America Cell and Gene Therapy CDMO Market Value Share (%), by Country, 2024
Figure 11: Europe Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 12: Europe Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 13: Europe Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 14: Europe Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 15: Europe Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 16: Europe Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 17: Asia Pacific Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 18: Asia Pacific Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 19: Asia Pacific Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 20: Asia Pacific Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 21: Asia Pacific Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 22: Asia Pacific Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 23: Latin America Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 24: Latin America Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 25: Latin America Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 26: Latin America Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 27: Latin America Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 28: Latin America Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 29: Middle East & Africa Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 30: Middle East & Africa Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 31: Middle East & Africa Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 32: Middle East & Africa Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 33: Middle East & Africa Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 34: Middle East & Africa Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 35: Global Cell and Gene Therapy CDMO Market Share (%), by Company, 2025
List of Tables
Table 1: Global Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 2: Global Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 3: Global Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 4: North America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 5: North America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 6: North America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 7: Europe Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 8: Europe Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 9: Europe Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 10: Asia Pacific Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 11: Asia Pacific Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 12: Asia Pacific Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 13: Latin America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 14: Latin America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 15: Latin America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Middle East & Africa Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 17: Middle East & Africa Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 18: Middle East & Africa Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035